EarningsQ2 2026 Earnings Report
MX:ONCN Q2 2026 EPS Results
Actual EPS$37.23
Consensus EPS$30.16
Beat/MissBeat by +$7.06
One Year Ago EPS$16.53
MX:ONCN Q2 2026 Revenue Results
Actual Revenue$31.02B
Expected Revenue$29.50B
Beat/MissBeat by +$1.51B
YoY Revenue Growth+29.39%
Earnings Announcement Details
QuarterQ2 2026
Date08/05/2026
TimeBefore Open
Conference CallWednesday, August 5, 2026
MX:ONCN Upcoming Earnings
BeOne Medicines's next earnings date is estimated for October 31, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:ONCN Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a strongly positive commercial and financial picture: robust revenue and EPS growth, raised full‑year guidance, doubled free cash flow, high gross margins, and multiple meaningful regulatory and late‑stage pipeline milestones (MANGROVE result, BEQALZI approval, BTK degrader progress). Headwinds and uncertainties were present but limited relative to the strength described — including a missed uMRD superiority in CELESTIAL‑301 (though PFS remains the primary endpoint), a $60 million tax settlement, increased operating expense guidance to fund pipeline investment, and ongoing competitive dynamics. On balance, the company emphasized durable demand for BRUKINSA, expanding global footprint, and an accelerating late‑stage pipeline, leading to an overall favorable outlook.Company Guidance
Strong Top-Line Growth
Total revenue of $1.7 billion in Q2 2026, representing 30% year-over-year growth.
Material EPS Expansion
GAAP diluted earnings per ADS were $2.05, up 144% versus $0.84 a year ago; adjusted diluted EPS were $3.84 versus $2.25 prior year.
BRUKINSA Commercial Momentum
BRUKINSA global revenues exceeded $1.2 billion in Q2, up 31% year-over-year; #1 BTK inhibitor in the U.S. and globally, treating >300,000 patients across 80+ markets and approved in five B-cell malignancy indications.
Raised Full-Year 2026 Guidance
Revenue guidance increased by $300 million to $6.6–$6.8 billion; GAAP operating income guidance increased by $250 million to $1.0–$1.1 billion (non-GAAP operating income $1.7–$1.8 billion).
Improving Adjusted Profitability
Adjusted income from operations rose to $503 million (>80% growth YoY); adjusted net income $444 million.
Strong Cash Generation
Free cash flow doubled year-over-year to $435 million in the quarter.
Broad Geographic Growth
U.S. revenue ~ $899 million (31% YoY); China ~ $500 million (17% YoY; FX added ~7% of reported growth); Europe ~ $208 million (37% YoY); Rest of World ~ $73 million (more than doubled).
High Gross Margins and Profitability
Gross profit of $1.5 billion with gross margin just under 90%; income from operations grew to $325 million and net income was $237 million (includes tax audit settlement impact).
Regulatory and Pipeline Milestones
FDA approval of BEQALZI (first/only BCL-2 inhibitor in mantle cell lymphoma); MANGROVE Phase III positive for BRUKINSA chemo‑free regimen (ZR vs BR HR reported as 0.57); Tacabrutideg (BTK degrader) tracking toward potential accelerated approval submission in relapsed/refractory CLL by year‑end.
Commercial Portfolio Diversification
TEVIMBRA generated $229 million (18% YoY growth) and Amgen in‑licensed portfolio delivered $157 million (25% YoY growth).
Robust R&D Progress and Late-Stage Starts
Multiple solid tumor programs advancing to registrational trials or Phase III (CDK4 inhibitor in Phase III, GPC3 x 4-1BB enrollment for China registration cohort, B7-H4 ADC planned for pivotal study in ovarian cancer before year-end).
Large Real-World Evidence Supporting BRUKINSA
Medicare real-world analysis of >10,500 previously untreated CLL patients showed BRUKINSA associated with a 24% and 36% reduction in risk of death versus acalabrutinib and ibrutinib, respectively; study published in a peer-reviewed journal.
Manufacturing Investment
Announced $300 million expansion of U.S. manufacturing site in Hopewell, New Jersey to support growth.
MX:ONCN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed